[Progress in research on tumor immune PD-1/PD-L1 signaling pathway in malignant bone tumors]

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Programmed death receptor 1 (PD-1) and its ligand PD-L1 are crucial in tumor immune evasion.
• PD-1/PD-L1 blockade demonstrates significant clinical efficacy across various malignancies.
• This pathway is a promising target for cancer immunotherapy.

Purpose of the Study:

• To elucidate the role of PD-1/PD-L1 signaling in tumor immunity.
• To analyze the therapeutic potential of PD-1/PD-L1 antibodies in malignant bone tumors.
• To provide a theoretical basis for PD-1/PD-L1 targeted therapy in bone cancers.

Main Methods:

• Literature review focusing on PD-1/PD-L1 signaling mechanisms.
• Analysis of existing clinical research on PD-1/PD-L1 blockade in various cancers.
• Exploration of the application prospects in malignant bone tumors.

Main Results:

• PD-1/PD-L1 pathway is a validated target in several cancers like melanoma and lung cancer.
• Limited research currently exists on PD-1/PD-L1 immunotherapy for malignant bone tumors.
• The clinical progress of PD-1/PD-L1 blockade in bone tumors requires further investigation.

Conclusions:

• PD-1/PD-L1 blockade holds promise as an immunotherapy strategy for malignant bone tumors.
• Further research is essential to fully understand and leverage this pathway for bone cancer treatment.
• This review aims to guide future therapeutic development in China.